



## Evidence reviews to support NHS England commissioning policies

Commissioning support Published: 23 March 2021

www.nice.org.uk

These evidence reviews were developed to support the following NHS England commissioning policies. NICE has conducted a <u>more recent review of the evidence for its</u> rapid guideline.

## NHSE commissioning policies

- Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older)
- Interim Clinical Commissioning Policy: Tocilizumab for hospitalised patients with COVID-19 pneumonia (adults)
- <u>Interim Clinical Commissioning Policy: Sarilumab for critically ill patients with COVID-19</u> pneumonia (adults).

Download the associated evidence reviews:

- ES27 Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19
- ES33 Tocilizumab for COVID-19
- ES34 Sarilumab for COVID-19.